Symberix Featured in PNAS Articles

 Symberix Featured in Two PNAS Articles

Durham, NC (April 28, 2020) - A review article published in PNAS highlights Symberix's efforts to understand the role of the human microbiota in drug efficacy and toxicity. Symberix co-founder Matt Redinbo is featured in the article alongside other leaders from the emerging field of “pharmacomicrobiomics” -- the study of mechanisms behind the microbial impact on drug metabolism.

"Using a combination of chemistry and genomics, researchers are now beginning to identify these mechanisms. As they do, they’re uncovering ways to inhibit the microbial enzymes that cause distressing side effects. The end result could be drugs that are less toxic, as well as better predictions about how patients respond to medications."

Symberix co-founder Matt Redinbo also published a research article in PNAS in March 2020 describing microbiota-targeted therapeutics that inhibit gut bacterial β-glucuronidases to enhance anticancer drug efficacy.

Symberix, Inc. is a biopharmaceutical company focused on developing the first generation of gut microbiome-targeting drugs to treat lower GI disorders. Gut microbes express numerous proteins, including a family of bacterial β-glucuronidase enzymes capable of generating toxic metabolites of many common medications in the lower GI tract. Symberix is developing bacterial β-glucuronidase inhibitors as adjunctive therapy to mitigate drug-induced toxicities and is exploring their use as monotherapy for other lower GI disorders, such as inflammatory bowel disease. Symberix’s internal team and external advisors have a deep understanding of the biology of the gut microbiome, and extensive drug discovery and clinical development experience.

Contact:
Greg Mossinghoff
Chief Business Officer
Symberix, Inc.
Greg.Mossinghoff@Symberix.com